Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00999037 · ClinicalTrials.gov registry record · NA
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
A NA study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT00999037 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 18 participants.
The verdict
NCT00999037, a NA study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
FGF-23 is a newly described protein that is an important regulator of phosphorus in the body. This protein increases in people with kidney disease and people who need dialysis have very high levels of FGF-23 in the blood. However, although some studies have indicated that FGF-23 levels go up with increased intake of phosphorus, no one knows if FGF-23 levels can be lowered in patients with kidney disease by preventing them from absorbing phosphorus from food. This study is designed to see what happens to levels of FGF-23 in the blood when patients with chronic kidney disease take medications to prevent phosphorus absorption. Since high levels of FGF-23 have been linked with increased rates of death in patients with advanced kidney disease, controlling the levels may, in the future, be a way to decrease heart disease in patients with kidney disease.
Interventions
- OTHER Placebo
- DRUG Sevelamer Carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-10 |
| Est. Completion | 2015-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00999037
The ClinicalTrials.gov registry entry for NCT00999037 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00999037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00999037 about?
NCT00999037 is a clinical study titled "FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease". FGF-23 is a newly described protein that is an important regulator of phosphorus in the body. This protein increases in people with kidney disease and people who need dialysis have very high levels of FGF-23 in the blood. However, although some studies have indicated that FGF-23 levels go up with in...
What is the current status of trial NCT00999037?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2009-10. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00999037?
The interventions under investigation include: Placebo (OTHER), Sevelamer Carbonate (DRUG).
Who is sponsoring clinical trial NCT00999037?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.